• Home
  • About +
    • Our Story
    • Meet the Team
    • FAQs
  • Our Science +
    • Inhaled IFN-β
    • Clinical Trials
    • Publications
  • Investors +
    • Share Price Information
    • Reports & Presentations
    • Investor News
    • Shareholder Information
    • AIM Rule 26
    • Corporate Governance
    • Investor Calendar
  • News +
    • Press Releases
    • Resources
    • Factsheets
    • TR-1/Options Press Releases
  • Careers
  • Contact
  • Home
  • About
  • Our Science
  • Investors
  • News
  • Careers
  • Contact
  • Our Story
  • Meet the Team
  • FAQs
  • Inhaled IFN-β
  • Clinical Trials
  • Publications
  • Share Price Information
  • Reports & Presentations
  • Investor News
  • Shareholder Information
  • AIM Rule 26
  • Corporate Governance
  • Investor Calendar
  • Press Releases
  • Resources
  • Factsheets
  • TR-1/Options Press Releases
← Back to Media

In the News

Read our CEO Richard Marsden's 2023 Letter
5th January 2023
The Need - and Opportunity - to Develop Broad-Spectrum Antivirals by Dr Phillip Monk
3rd January 2023
ITN Lungs Matter
28th November 2022
Synairgen to play key role in respiratory viral infection study
5th September 2022
WebMD's John Whyte MD talks to Synairgen CEO Richard Marsden
28th December 2021
Synairgen founder Professor Sir Stephen Holgate talks to John Whyte MD of WebMD
28th December 2021
Synairgen presents data on antiviral activity of lead asset
8th December 2021
Synairgen 'delighted' to get green light for US government-sponsored Phase III trials, starting soon
20th October 2021
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
24th May 2021
  • Our Science
  • Interferon Beta
  • Investigating antiviral treatment in COVID-19
  • Investigating antiviral treatment in COPD
  • Investigating antiviral treatment in asthma
  • Relevant Publications
  • About
  • Home
  • Our Story
  • Team
  • FAQs
  • Careers
  • Contact
  • Investors
  • Investors Overview
  • Performance
  • Reports & Presentations
  • Investor News
  • Analysts
  • Investor Calendar
  • News
  • Press Releases
  • Factsheets
  • Resources
Cookie PolicyLegalPrivacy Policy
© Synairgen plc. All Rights ReservedRegistered in England and Wales No. 5233429 | Site by Ether